ClinicalTrials.gg
RecruitingNCT07359898IntensiveUpdated Jul 24, 2026

International Multicenter Study of the Navitor/Navitor Vision Transcatheter Aortic Valve Platform

An observational study in Severe Native Aortic Stenosis, sponsored by IRCCS Policlinico S. Donato. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-24.

Sponsored by IRCCS Policlinico S. Donato · Observational

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 118 studies in Aortic Valve Stenosis with a site in Italy — 39 open to participants now, 54 under way, 1 of them phase 3. Aortic Valve Stenosis · Italy.

Planned enrollment
17th of 71
1,000 · median 500
Started
2025
with 9 others
Observational
71 of 118
21 open now
Primary completion
2027-10
later than 38 of 53 live
Registered
111th of 118
by date
Lead sponsor
5 of 118
IRCCS Policlinico S. Donato

Among the 118 studies in Aortic Valve Stenosis with a site in Italy, this one is the 17th largest by planned enrollment of the 71 observational ones that give a count, is one of 10 that started in 2025, is one of 71 observational ones, reaches primary completion later than 38 of the 53 other live ones, and was the 111th registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

39 of the 118 studies in Aortic Valve Stenosis with a site in Italy are open now. Recruiting first, the newest first:

33 more — sign in →

All 39 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 118 studies in Aortic Valve Stenosis with a site in Italy, or all of them as a file.
02

Study summary

INTENSIVE is a prospective, single-arm, multi-center, international, investigator-initiated study of the Navitor/Navitor Vision Transcatheter Aortic Valve (Navitor/Navitor Vision Valve) in patients with symptomatic, severe native aortic stenosis to monitor the outcomes of this valve in a real-world clinical setting.

Read the detailed description

This comprehensive data collection across 25 interventional centers, aligned with standard clinical care practices, seeks to provide an objective benchmark for current TAVR practice.

The Navitor System includes the Navitor Transcatheter Aortic Valve (23 mm, 25 mm, 27 mm, 29 mm, and 35 mm), FlexNav Delivery System (small and large), and Navitor Loading System (small, large, and LG+). The FlexNav Delivery System (small and large) is commercially available in Europe. The 23 mm, 25 mm, 27 mm, 29 mm, and 35 mm valves and their loading systems are currently CE marked.

The Navitor Valve maintains several design features of the first-generation Portico Valve including the same valve sizes and range of use (except for the addition of the 35 mm valve to expand the use range), open stent cell design to provide easy coronary access and blood flow, repositionable with the ability to re-sheath and retrieve, leaflets derived from pericardial bovine tissue, and intra-annular placement of leaflets/cuff within the stent frame for early valve function to maintain hemodynamic stability during implantation.

The Study will enroll subjects that, after comprehensive Heart Team evaluation, are scheduled for treatment with the Navitor/Navitor Vision Valve according to the standard of care at up to 25 experienced TAVI implant centers across Europe and the UK. All sites must either have prior Portico or Navitor/Navitor Vision TAVI system experience. Subjects who provide informed consent for the collection of their clinical data in this Study will undergo Navitor/Navitor Vision Valve implantation via a transfemoral or alternative access (subclavian or axillary) approach using the site's anesthesia protocol for TAVI procedures.

In the Study, the point of enrollment is defined as signing of informed consent, whereas the point of registration is defined as the insertion of the FlexNav Delivery System (loaded with a Navitor/Navitor Vision Valve) into the subject's vasculature (the subject is considered to have undergone an attempted Navitor/Navitor Vision Valve implantation at this point). Only registered subjects will be included in the analysis.

The endpoints of interest will be defined according to VARC-3 definitions. Subjects participating in the Study will be followed for a total of 5 years with data collected at baseline, procedure, prior to hospital discharge, and follow-up at 30 days, 12 months and annually thereafter up to 5 years.

The expected duration of enrollment is 12 months, and the total duration of the Study including final data cleaning, reporting, and site close-out is expected to be approximately 6.5 years.

This Study will enroll subjects of all genders who have symptomatic severe AS, either in a native valve or in a surgical bioprosthetic valve, and who have an indication for TAVI. The latter may also be predominantly regurgitant and remain suitable for enrolment. Subjects must meet all general eligibility criteria for the TAVI procedure and provide written informed consent before sites collect any clinical data for this Study.

The operative risk determination of study candidates will be done by the local heart team. The assessment of surgical risk will include the Society of Thoracic Surgeons (STS) Adult Cardiac Surgery Risk Calculator score and/or EuroSCORE II, indices of frailty, and comorbidities not captured by risk calculators, as described below, and current TAVI practice guidelines. A member of the site's clinical investigation team previously trained on the protocol must evaluate patients for the general eligibility criteria and, if applicable, enter them into the site-specific Pre-Screening Log. A patient who does not satisfy all general eligibility criteria prior to informed consent is considered a screen failure and should not be enrolled in the Study.

Sites will ask patients meeting all general inclusion criteria and no general exclusion criteria to sign an Informed Consent form following the established Informed Consent process if they wish to participate in the Study.

A patient is considered enrolled in the Intensive Study from the moment the patient provides written informed consent.

Each subject meeting all general eligibility criteria who is enrolled and receives the Navitor valve shall be followed up until completion of the recommended 5-year follow-up period; however, a subject's participation in any clinical study is voluntary and the subject has the right to withdraw at any time without penalty or loss of benefit. Conceivable reasons for discontinuation may include, but are not limited to, the following:

  • Subject death
  • Subject undergoes the interventional procedure but exits the operating room without an implanted Navitor Valve; in this case, follow-up is limited to 30 days post-procedure for safety assessment
  • After Navitor implantation, subject receives another aortic valve intervention during follow-up (e.g., valve-in-valve intervention, surgical AVR, etc.); in this case, follow-up is limited to 30 days after the additional procedure for safety assessment
  • Subject voluntary withdrawal
  • Subject lost to follow-up as described below
  • Subject's follow-up is terminated Sites must collect and document the reason(s) for subject discontinuation. Investigators must also report this to their respective EC as defined by their institution's procedure(s).

No additional follow-up or data collection is required for subjects once withdrawn from the Study, except for the status (deceased/alive).

If a subject withdraws consent, the site should attempt to schedule the subject for a final follow-up visit. At this final follow-up visit, the subject will undergo the following routine assessments, and related data will be collected when available:

  • Echocardiography, including a comprehensive transthoracic echocardiogram, including assessment of aortic valve gradients (mean and peak), areas, indices, degree of regurgitation, cardiac output and cardiac index, left ventricular systolic function (global and segmental)
  • Adverse event assessment
03

Conditions studied

  • Severe Native Aortic Stenosis

Keywords

  • Aortic Stenosis
  • TAVI
  • Navitor
  • Portico
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

This Study will enroll subjects of all genders who have symptomatic severe AS, either in a native valve or in a surgical bioprosthetic valve, and who have an indication for TAVI. The latter may also be predominantly regurgitant and remain suitable for enrolment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is referred to undergo TAVI with a Navitor/Navitor Vision valve according to the local Heart Team. The Heart Team determines the indication for TAVI with Navitor/Navitor Vision before possible enrolment and independently of the study.
  2. Subject is of legal age for consent in the host country.
  3. Subject has been informed of the nature of the study, agrees to its provisions, and has provided written as approved by the Ethics Committee (EC) of the respective clinical site.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or nursing subjects
  2. Need for emergency surgery for any reason
  3. to Navitor/Navitor Vision TAVI according to the IFU:

    1. Any sepsis, including active endocarditis
    2. Any evidence of left ventricular or atrial thrombus
    3. Vascular conditions (i.e., stenosis, tortuosity, or severe calcification) that make insertion and endovascular access to the aortic valve impossible
    4. Non-calcified aortic annulus
    5. Any leaflet configuration other than tricuspid
    6. Inability to tolerate antiplatelet/anticoagulant therapy
  4. Incapacitated individuals, defined as persons who are mentally ill, mentally handicapped, individuals with severe dementia or individuals without legal authority
  5. Individuals who are unable to read or write
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • Aortic Stenosis Patients

    This Study will enroll subjects of all genders who have symptomatic severe AS, either in a native valve or in a surgical bioprosthetic valve, and who have an indication for TAVI. The latter may also be predominantly regurgitant and remain suitable for enrolment. Subjects must meet all general eligibility criteria for the TAVI procedure and provide written informed consent before sites collect any clinical data for this Study. The operative risk determination of study candidates will be done by the local heart team. The assessment of surgical risk will include the Society of Thoracic Surgeons (STS) Adult Cardiac Surgery Risk Calculator score and/or EuroSCORE II, indices of frailty, and comorbidities not captured by risk calculators, as described below, and current TAVI practice guidelines.

06

What researchers measure

Primary outcomes

  1. All-Cause Mortality

    The primary endpoint is all-cause mortality at 12 months after the index Navitor/Navitor Vision implantation procedure.

    Time frame: 12 months

Secondary outcomes

  1. Valve Academic Research Consortium 3 (VARC-3) event definitions

    Secondary (Descriptive) Endpoints: The rate of the following key outcomes for the Study will be assessed as descriptive endpoints: 1. Composite of all-cause mortality, fatal stroke/stroke with disability, type 3/type 4 bleeding, stage 3/stage 4 acute kidney injury, major vascular complications, or major access-related non-vascular complications at 30 days 2. Composite of all-cause mortality or all stroke at 12 months 3. Procedural success defined as successful vascular access, delivery and deployment of the Valve; retrieval of the delivery system and correct positioning of a single Valve in the proper anatomical location and the absence of procedural mortality 4. Mortality at 30 days and 12 months 5. Stroke at 30 days and 12 months 6. Transient ischemic attack (TIA) at 30 days and 12 months 7. Bleeding 8. Major vascular complications at 30 days 9. Major access-related non-vascular complications at 30 days 10. Major cardiac complications at 30 days

    Time frame: 30 days and 12 months

  2. Valve Academic Research Consortium 3 (VARC-3) event definitions

    11\. Acute kidney injury (stage 4, stage 3, and stage 2) at 30 days 12. Permanent pacemaker insertion at 30 days and 12 months 13. Myocardial infarction at 30 days and 12 months 14. Coronary obstruction requiring intervention at 30 days and 12 months 15. Difference in coronary artery cannulation time before versus after Navitor/Navitor Vision implantation 16. Differences in outcome of PVL, embolization/migration 17. Assessment of PM dependency at 3 months after implantation 18. Vascular access complication rate according to the "Hostile Score" 19. Changes in functional status from baseline to follow-up assessments at 30 days and 12 months (e.g., New York Heart Association (NYHA) functional classification, quality of life measure: Kansas City Cardiomyopathy Questionnaire (KCCQ)) 20. Rehospitalization (procedure-related or valve-related hospitalization, and other cardiovascular hospitalization) at 30 days and 12 months

    Time frame: 30 days, 3 months, and 12 months

  3. Valve Academic Research Consortium 3 (VARC-3) event definitions

    21\. Paravalvular leak (none/trace, mild, moderate or severe) at discharge, 30 days, 12 months and annually (when collected) through 5 years 22. Changes in echocardiographic parameters from baseline to follow-up at 30 days, 12 months and annually (when collected) through 5 years (e.g., mean effective orifice area, mean transvalvular gradient) 23. Aortic valve reintervention at 30 days, 12 months, and annually through 5 years 24. Prosthetic valve endocarditis at 12 months and annually through 5 years 25. Structural valve deterioration at 12 months and annually through 5 years 26. Non-structural valve dysfunction at 12 months and annually through 5 years 27. Successful coronary access as needed at 12 months and annually through 5 years 28. Clinically significant prosthetic valve thrombosis at 12 months and annually through 5 years

    Time frame: 30 days, 12 months and annually through 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Oct 2027, 24 months after the start.

Of 206 non-industry observational studies under Aortic Valve Stenosis, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 120. This study's planned 24 months is below that.

Counting every sponsor, half of 243 studies reached it within 44 months; a quarter within 23 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2025
First posted
Jan 22, 2026
StartActual
Oct 11, 2025
Primary completionEst.
Oct 2027
CompletionEst.
Oct 2031
Last update
Jul 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07359898
Collaborators
Abbott, Meditrial SrL
Responsible party
Sponsor
First posted
Jan 22, 2026
Start date
Oct 11, 2025
Primary completion
Oct 2027 (estimated)
Completion
Oct 2031 (estimated)
Last update
Jul 24, 2026

Study contacts

Luca Testa, Principal Investigator
Contact
luca.testa@grupposandonato.it
00390252774980

Oversight

Data monitoring committee
No
FDA-regulated drug
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion